Figure 1: Vte Risk With Drospirenone And Ethinyl Estradiol Relative To Lng-containing Cocs (adjusted Risk#) (Drospirenone Fig1)
Zumandimine Kit
Product Images NDC 59651-030
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Zumandimine (NDC 59651-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 Likelihood Of Developing A Vte (Drospirenone Fig2)
This appears to be medical data related to the likelihood of blood clots in women who are non-pregnant and not using COC. The data provides ranges from 105 to 3109 blood clots out of 10,000 women years. Data for postpartum women is limited to 12 weeks. The pregnancy data is based on the actual duration of pregnancy in reference studies and the rate of blood clots is estimated to be between 7 to 27 per 0,000 women years based on the assumption that pregnancy duration is nine months.*
Figure3 (Drospirenone Fig3)
Drospirenone-fig4 (Drospirenone Fig4)
This text appears to be a comparison of different methods of birth control and their effectiveness in preventing pregnancy. It lists several methods, such as implants and injections, and notes the typical success rates in terms of the number of pregnancies per 100 women per year. The text also mentions other methods, such as birth control pills, condoms, and diaphragms, and discusses how adding additional methods, such as spermicide or withdrawal, can increase their effectiveness. Finally, it notes that some methods, such as no sex during the most fertile days of the cycle, can be less effective at preventing pregnancy. Overall, this text is a useful guide for individuals looking to choose the most effective method of birth control.*
Figure5 (Drospirenone Fig5)
Drospirenone-fig6 (Drospirenone Fig6)
Drospirenone-fig7 (Drospirenone Fig7)
Zumandimine® is a contraceptive tablet, containing 3mg of drospirenone USP and 0.60mg of ethinyl estradiol. The package contains 21 light pink to pink tablets, followed by 7 green tablets. The tablets are to be taken daily for 28 consecutive days per menstrual cycle. The product is intended to prevent pregnancy, but it does not protect against HIV infection (AIDS) or other sexually transmitted diseases. The package includes patient information labeling and day label stickers intended for the patient. Zumandimine® is manufactured in India.*
Drospirenone Fig8
Zumandimine® is an oral contraceptive medication containing drospirenone and ethinyl estradiol tablets. It comes in a package of 28 tablets, with 21 pink tablets containing 3 mg of drospirenone USP and 0.03 mg of ethinyl estradiol USP, and 7 green tablets. The medication is used to prevent pregnancy, but it does not protect against sexually transmitted diseases, including HIV infection. The usual dosage is one tablet daily for 28 consecutive days per menstrual cycle. The package contains patient information labeling, day label stickers, and the bister pack intended for the patient. This medication is manufactured by Aurobindo Pharmaceuticals.*
Structure (Drospirenone Str)
Drospirenone and Ethinyl Estradiol are two hormone ingredients commonly found in combination oral contraceptives. They work together to prevent pregnancy by inhibiting ovulation, thickening cervical mucus to prevent sperm from getting through, and thinning the lining of the uterus to prevent implantation.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
